These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 25908780)

  • 1. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
    Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
    Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD137, an attractive candidate for the immunotherapy of lung cancer.
    Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
    Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
    Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.
    Hong JP; Reynoso GV; Andhey PS; Swain A; Turner JS; Boon ACM; Krammer F; Ellebedy AH; Zanini F; Artyomov M; Hickman HD; Diamond MS
    Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32699843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
    Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
    Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
    Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention.
    Luu K; Shao Z; Schwarz H
    J Leukoc Biol; 2020 May; 107(5):731-738. PubMed ID: 32052477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
    Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
    Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
    Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
    Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
    Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.
    Sánchez-Paulete AR; Cueto FJ; Martínez-López M; Labiano S; Morales-Kastresana A; Rodríguez-Ruiz ME; Jure-Kunkel M; Azpilikueta A; Aznar MA; Quetglas JI; Sancho D; Melero I
    Cancer Discov; 2016 Jan; 6(1):71-9. PubMed ID: 26493961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
    Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
    Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
    Chester C; Sanmamed MF; Wang J; Melero I
    Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
    Kohrt HE; Houot R; Goldstein MJ; Weiskopf K; Alizadeh AA; Brody J; Müller A; Pachynski R; Czerwinski D; Coutre S; Chao MP; Chen L; Tedder TF; Levy R
    Blood; 2011 Feb; 117(8):2423-32. PubMed ID: 21193697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.